☆ 4.6 Letter

Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression

THROMBOSIS RESEARCH (2022)

Get Full Text
Add to Collection

Journal

THROMBOSIS RESEARCH
Volume 213, Issue -, Pages 170-172

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2022.03.021

Keywords

Alirocumab; FVIII; LDLR; LRP1; Statins

Categories

Hematology Peripheral Vascular Disease

Funding

  1. Pfizer Global Medical Grant [60322595]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.